Terms: = Lung cancer AND RBM15, Q96T37, 64783, ENSG00000162775, OTT, OTT1
24 results:
1. Regulatory mechanism of RNA binding motif protein 15-mediated N
Chen J
Environ Toxicol; 2023 Nov; 38(11):2545-2559. PubMed ID: 37471637
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic Value and Genome Signature of m6A/m5C Regulated Genes in Early-Stage lung Adenocarcinoma.
Tian L; Wang Y; Tian J; Song W; Li L; Che G
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047493
[TBL] [Abstract] [Full Text] [Related]
3. A prognostic model based on ferroptosis-related long non-coding RNA signatures and immunotherapy responses for non-small cell lung cancer.
Yi WW; Guo XQ; Xu Y; Liang B; Song P
Eur Rev Med Pharmacol Sci; 2023 Mar; 27(6):2591-2604. PubMed ID: 37013777
[TBL] [Abstract] [Full Text] [Related]
4. rbm15 silencing promotes ferroptosis by regulating the TGF-β/Smad2 pathway in lung cancer.
Feng J; Li Y; He F; Zhang F
Environ Toxicol; 2023 Mar; 38(4):950-961. PubMed ID: 36715115
[TBL] [Abstract] [Full Text] [Related]
5. The prognostic value of N6-methyladenosine rbm15 regulators in lung adenocarcinoma.
Ma M; Wang W; Wang B; Yang Y; Huang Y; Zhao G; Ye L
Cell Mol Biol (Noisy-le-grand); 2022 May; 68(1):130-139. PubMed ID: 35809319
[TBL] [Abstract] [Full Text] [Related]
6. 29 m
Liu M; Xu K; Saaoud F; Shao Y; Zhang R; Lu Y; Sun Y; Drummer C; Li L; Wu S; Kunapuli SP; Criner GJ; Sun J; Shan H; Jiang X; Wang H; Yang X
J Immunol Res; 2022; 2022():1433323. PubMed ID: 35211628
[TBL] [Abstract] [Full Text] [Related]
7. Expression and prognostic significance of m6A-related genes in TP53-mutant non-small-cell lung cancer.
Zhao Z; Wan J; Guo M; Wang Y; Yang Z; Zhou F; Li Z; Ming L
J Clin Lab Anal; 2022 Jan; 36(1):e24118. PubMed ID: 34812534
[TBL] [Abstract] [Full Text] [Related]
8. Gene and prognostic value of N6-methyladenosine (m6A) modification regulatory factors in lung adenocarcinoma.
Zhang D; Zhang D; Wang C; Yang X; Zhang R; Li Q; Xiong Y
Eur J Cancer Prev; 2022 Jul; 31(4):354-362. PubMed ID: 34519693
[TBL] [Abstract] [Full Text] [Related]
9. Can Personalized Neoantigens Raise the T Cell Bar?
Zaidi N
Cell; 2020 Oct; 183(2):301-302. PubMed ID: 33064984
[TBL] [Abstract] [Full Text] [Related]
10. Molecular characterization, biological function, tumor microenvironment association and clinical significance of m6A regulators in lung adenocarcinoma.
Li Y; Gu J; Xu F; Zhu Q; Chen Y; Ge D; Lu C
Brief Bioinform; 2021 Jul; 22(4):. PubMed ID: 33003204
[TBL] [Abstract] [Full Text] [Related]
11. Diagnostic, progressive and prognostic performance of m
Zhuang Z; Chen L; Mao Y; Zheng Q; Li H; Huang Y; Hu Z; Jin Y
Int J Biol Sci; 2020; 16(11):1785-1797. PubMed ID: 32398949
[No Abstract] [Full Text] [Related]
12. Bioinformatics Analysis of Microarray Datasets to Identify Prognostic Factors in lung Adenocarcinoma.
Jin X; Xu L; Guan Y; Zhang Z; Li H
DNA Cell Biol; 2020 Jun; 39(6):965-974. PubMed ID: 32330391
[TBL] [Abstract] [Full Text] [Related]
13. Radiation dose escalation with modified fractionation schedules for locally advanced NSCLC: A systematic review.
Zehentmayr F; Grambozov B; Kaiser J; Fastner G; Sedlmayer F
Thorac Cancer; 2020 Jun; 11(6):1375-1385. PubMed ID: 32323484
[TBL] [Abstract] [Full Text] [Related]
14. Expression and Prognostic Significance of m6A-Related Genes in lung Adenocarcinoma.
Zhang Y; Liu X; Liu L; Li J; Hu Q; Sun R
Med Sci Monit; 2020 Feb; 26():e919644. PubMed ID: 32086933
[TBL] [Abstract] [Full Text] [Related]
15. Pulmonary Oligometastases Treated by Stereotactic Body Radiation Therapy: A Nationwide Survey of 1,378 Patients.
Niibe Y; Yamamoto T; Onishi H; Yamashita H; Katsui K; Matsumoto Y; Oh RJ; Aoki M; Shintani T; Yamada K; Kobayashi M; Ozaki M; Manabe Y; Yahara K; Nishikawa A; Kakuhara H; Yamamoto K; Inoue T; Takada YU; Nagata K; Suzuki O; Terahara A; Jingu K
Anticancer Res; 2020 Jan; 40(1):393-399. PubMed ID: 31892592
[TBL] [Abstract] [Full Text] [Related]
16. Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC.
Zhao Q; Chen G; Ye L; Shi S; Du S; Zeng Z; He J
Radiat Oncol; 2019 May; 14(1):86. PubMed ID: 31133034
[TBL] [Abstract] [Full Text] [Related]
17. Molecular analysis of an asbestos-exposed Belgian family with a high prevalence of mesothelioma.
Hylebos M; Op de Beeck K; van den Ende J; Pauwels P; Lammens M; van Meerbeeck JP; Van Camp G
Fam Cancer; 2018 Oct; 17(4):569-576. PubMed ID: 29961174
[TBL] [Abstract] [Full Text] [Related]
18. PORTAF - postoperative radiotherapy of non-small cell lung cancer: accelerated versus conventional fractionation - study protocol for a randomized controlled trial.
Bütof R; Simon M; Löck S; Troost EGC; Appold S; Krause M; Baumann M
Trials; 2017 Dec; 18(1):608. PubMed ID: 29262836
[TBL] [Abstract] [Full Text] [Related]
19. Individualized dose prescription for hypofractionation in advanced non-small-cell lung cancer radiotherapy: an in silico trial.
Hoffmann AL; Troost EG; Huizenga H; Kaanders JH; Bussink J
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1596-602. PubMed ID: 22245206
[TBL] [Abstract] [Full Text] [Related]
20. Does overall treatment time impact on survival after whole-brain radiotherapy for brain metastases?
Nieder C; Andratschke NH; Spanne O; Geinitz H; Grosu AL
Clin Transl Oncol; 2011 Dec; 13(12):885-8. PubMed ID: 22126732
[TBL] [Abstract] [Full Text] [Related]
[Next]
